Register Login

Sage Therapeutics Inc (SAGE)

  • Event
  • June 01, 2022, 11:16 UTC

(10% Negative) Sage Therapeutics, Inc. (SAGE) Announces Delay in importance Trials for depressive symptoms at Day 15 Due to Pandemic-Related Challenges, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 12:11 a.m.

    📋 Sage Therapeutics, Inc. (SAGE) - Clinical Trial Update

    Filing Date: 2022-06-01

    Accepted: 2022-06-01 07:16:01

    Event Type: Clinical Trial Update

    Event Details:

    Sage Therapeutics Inc (SAGE) Announces Clinical Trial Update Sage Therapeutics Inc (SAGE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: importance, Institutes
    • Diseases/Conditions: depressive symptoms at Day 15, Medical Research in Manhasset
    • Clinical Stage: Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process
    • Collaboration: the Phase 3 SKYLARK Study of Zuranolone
      • anticipated in early 2023

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Sage Therapeutics Inc
    • CIK: 0001597553
    • Ticker Symbol: SAGE
    • Period End Date: 2022-06-01
    • Document Type: 8-K

Search

News categories